JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB247193

Dengue Virus IgM ELISA kit (µ-capture)

Be the first to review this product! Submit a review

|

(0 Publication)

Dengue Virus IgM ELISA kit (µ-capture) is an indirect ELISA for the qualitative detection of IgM class antibodies against Dengue Virus in human plasma and serum samples.

- Colorimetric readout - 450 nm - Works on any standard plate reader
- Easy results interpretation

Key facts

Detection method

Colorimetric

Sample types

Citrate plasma, Heparin Plasma, Serum

Reacts with

Human

Assay type

Sandwich (qualitative)

Assay Platform

Pre-coated microplate (12 x 8 well strips)

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "sELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Dengue Virus IgM ELISA kit (μ-capture) (ab247193) is designed for the qualitative determination of IgM class antibodies against Dengue Virus in human serum or plasma (citrate, heparin).

The qualitative immunoenzymatic determination of specific antibodies is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique. Microplates are coated with specific antigens to bind corresponding antibodies of the sample. After washing the wells to remove all unbound sample material a horseradish peroxidase (HRP) labelled conjugate is added. This conjugate binds to the captured antibodies. In a second washing step unbound conjugate is removed. The immune complex formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product. The intensity of this product is proportional to the amount of specific antibodies in the sample. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450/620 nm is read using an ELISA microwell plate reader.

Dengue fever, also known as breakbone fever, is an infectious tropical disease caused by the dengue virus and transmitted by mosquitoes. Dengue fever virus (DENV) is a virus of the family Flaviviridae, genus Flavivirus and contains a single-stranded RNA genome with positive polarity. There are four serotypes of the virus, which are referred to as DENV-1, DENV-2, DENV-3 and DENV-4. The geographical distribution is around the equator, particularly Latin America, Central Africa, India, Southeast Asia, Western Pacific and South of the USA. Dengue viruses are transmitted to humans through the bites of infective female yellow fever mosquitoes (Stegomyia aegypti, formerly Aedes aegypti). The mosquitoes generally acquire the virus while feeding on the blood of an infected person. After virus incubation for eight to ten days, an infected mosquito is capable, during probing and blood feeding, of transmitting the virus for the rest of its life.

Yellow fever mosquitoes are well adapted to living in close proximity to humans, and to feeding off people rather than other vertebrates. They prefer to lay their eggs in artificial water containers, such as flower vases, uncovered barrels, buckets and discarded tires. The incubation period ranges from 3-14 days, but most often it is 4-7 days. Typically, people infected with dengue virus are asymptomatic or only have symptoms of a common cold. The characteristic symptoms of dengue are sudden-onset fever (up to 40 °C) with intense headache (especially behind the eyes), and muscle and joint pain. In combination with a skin rash these symptoms are known as the 'dengue triad'. This usually lasts 3-7 days. In some patients the disease proceeds to a critical phase. Dengue Hemorrhagic Fever (DHF) or Dengue Shock Syndrome (DSS) occur in less than 5 % of all cases of dengue. About 1-5 % of severe cases are fatal. In individual epidemics the case-fatality rate may reach up to 15 %. Infection with one serotype is believed to produce lifelong immunity to that serotype but only short-term protection against the others. Secondary infection with a different serotype may result in severe clinical manifestations. There is no vaccination available.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Precision

[ { "reproducibilityType": "Inter", "sample": "Sample", "replicates": 12, "mean": "8.96 nM", "standardDeviation": null, "coefficientOfVariability": "6.16" }, { "reproducibilityType": "Inter", "sample": "Sample", "replicates": 12, "mean": "18.77 nM", "standardDeviation": null, "coefficientOfVariability": "6.6" }, { "reproducibilityType": "Inter", "sample": "Sample", "replicates": 12, "mean": "5.32 nM", "standardDeviation": null, "coefficientOfVariability": "5.79" }, { "reproducibilityType": "Intra", "sample": "Sample", "replicates": 23, "mean": "0.53 nM", "standardDeviation": null, "coefficientOfVariability": "3.23" }, { "reproducibilityType": "Intra", "sample": "Sample", "replicates": 24, "mean": "1.019 nM", "standardDeviation": null, "coefficientOfVariability": "2.44" }, { "reproducibilityType": "Intra", "sample": "Sample", "replicates": 24, "mean": "0.986 nM", "standardDeviation": null, "coefficientOfVariability": "2.75" } ]

What's included?

{ "values": { "1x96Tests": { "sellingSize": "1 x 96 Tests", "publicAssetCode":"ab247193-1x96Tests", "assetComponentDetails": [ { "size":"1 x 1 Vial", "name":"Dengue Virus Antigen", "number":"AB247193-CMP02", "productcode":"" }, { "size":"1 x 50 mL", "name":"20X Washing Solution", "number":"AB247193-CMP09", "productcode":"" }, { "size":"1 x 15 mL", "name":"TMB Substrate Solution", "number":"AB247193-CMP08", "productcode":"" }, { "size":"1 x 100 mL", "name":"Sample Diluent", "number":"AB247193-CMP10", "productcode":"" }, { "size":"1 x 1 Unit", "name":"Dengue Virus Coated Microplate (IgM)", "number":"AB247193-CMP03", "productcode":"" }, { "size":"1 x 15 mL", "name":"Dengue Virus HRP conjugate", "number":"AB247193-CMP04", "productcode":"" }, { "size":"1 x 2 mL", "name":"IgM Negative Control", "number":"AB247193-CMP06", "productcode":"" }, { "size":"1 x 3 mL", "name":"IgM Cut-off Control", "number":"AB247193-CMP05", "productcode":"" }, { "size":"1 x 15 mL", "name":"Stop Solution", "number":"AB247193-CMP11", "productcode":"" }, { "size":"1 x 2 mL", "name":"IgM Positive Control", "number":"AB247193-CMP07", "productcode":"" }, { "size":"1 x 1 Unit", "name":"Cover Foil", "number":"AB247193-CMP01", "productcode":"" } ] } } }

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
+4°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Dengue Virus IgM also known as anti-Dengue IgM is an antibody target involved in the immune response against the Dengue virus. This immunoglobulin M (IgM) is produced soon after Dengue virus infection. While the exact mass of Dengue Virus IgM is not specific to a single value typical IgM has a mass of approximately 950 kDa. Dengue Virus IgM can be detected in human serum or plasma indicating an acute phase of infection. It's not a protein but an antibody produced by B cells when the immune system encounters the Dengue virus.
Biological function summary

Anti-Dengue IgM antibodies play a role in the early immune response to Dengue infection. They form part of the humoral immune system and contribute to pathogen neutralization. These antibodies can exist as pentameric complexes that enhance their ability to bind to the virus. Once produced they help prevent the virus from entering host cells and assist other components of the immune system in identifying and eliminating the virus. Their presence indicates an active or recent Dengue virus infection making them important in Dengue serology.

Pathways

Dengue Virus IgM is part of the immune pathway responding to viral infection. Such pathways include the complement activation pathway where IgM antibodies activate the complement system to eliminate pathogens efficiently. Additionally they can interact with Fc receptors on immune cells enhancing phagocytosis of the virus. Through these interactions Dengue Virus IgM aids in the broader adaptive immune response involving helper T cells and other immunoglobulins such as IgG.

Dengue Virus IgM is directly associated with Dengue fever an acute viral illness spread by mosquitoes. The presence of Dengue Virus IgM in a host is a clinical indicator of Dengue virus infection and plays an important role in diagnostic assessments using methods such as IgM capture ELISA or Dengue ELISA kits. This antibody can contribute to immune-mediated reactions such as immune enhancement where the presence of different non-neutralizing antibodies may facilitate severe illness. IgM aids in differentiating between primary and secondary Dengue infections which differ in severity and immune response potentially influencing the risk of developing more serious conditions such as Dengue hemorrhagic fever.

Product protocols

Target data

websiteProtocolBooklet
en

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com